PriceTargets.com logo

Perspective Therapeutics - CATX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 381.17%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 4 Strong Buy Ratings
$2.39 As of 12/4/2025 05:10 PM ET
▲ +0.18 (8.14%)

This chart shows the closing price for CATX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Perspective Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CATX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CATX

Analyst Price Target is $11.50
▲ +381.17% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Perspective Therapeutics in the last 3 months. The average price target is $11.50, with a high forecast of $16.00 and a low forecast of $7.00. The average price target represents a 381.17% upside from the last price of $2.39.

This chart shows the closing price for CATX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Perspective Therapeutics. This rating has held steady since January 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 3 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 3 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 4 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 4 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 4 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/21/2025UBS GroupReiterated RatingBuy ➝ Buy$18.00 ➝ $7.00
11/18/2025B. RileyLower TargetBuy ➝ Buy$12.00 ➝ $11.00
11/11/2025WedbushReiterated RatingOutperform$11.00
10/20/2025WedbushReiterated RatingOutperform$11.00
10/10/2025BTIG ResearchInitiated CoverageBuy ➝ Buy$14.00 ➝ $14.00
10/10/2025BTIG ResearchUpgradeBuy ➝ Strong-Buy$14.00 ➝ $14.00
10/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00
10/2/2025WedbushReiterated RatingOutperform$11.00
9/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00
9/15/2025WedbushReiterated RatingOutperform$11.00
7/12/2025Lifesci CapitalUpgradeStrong-Buy
6/23/2025B. RileyReiterated RatingBuy ➝ Buy$9.00 ➝ $12.00
6/23/2025WedbushReiterated RatingOutperform ➝ Outperform$11.00
6/3/2025Royal Bank Of CanadaUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00
5/14/2025Truist FinancialLower TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025WedbushReiterated RatingOutperform$11.00
4/7/2025Truist FinancialLower TargetBuy ➝ Buy$21.00 ➝ $10.00
3/31/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/27/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$16.00 ➝ $15.00
3/26/2025WedbushReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
3/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/17/2025WedbushReiterated RatingOutperform$11.00
3/13/2025HC WainwrightInitiated CoverageBuy$10.00
3/10/2025Brookline Capital ManagementUpgradeStrong-Buy
3/7/2025ScotiabankInitiated CoverageSector Outperform$15.00
3/6/2025Lifesci CapitalUpgradeStrong-Buy
3/4/2025Cantor FitzgeraldUpgradeStrong-Buy
2/5/2025Cantor FitzgeraldUpgradeStrong-Buy
1/24/2025WedbushReiterated RatingOutperform$11.00
1/14/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$16.00 ➝ $16.00
1/13/2025WedbushReiterated RatingOutperform$11.00
11/25/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$25.00 ➝ $16.00
11/25/2024Bank of AmericaDowngradeBuy ➝ Neutral$24.00 ➝ $5.00
11/22/2024OppenheimerLower TargetOutperform ➝ Outperform$22.00 ➝ $16.00
11/21/2024WedbushReiterated RatingOutperform$20.00 ➝ $11.00
10/24/2024WedbushReiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00
10/24/2024UBS GroupInitiated CoverageBuy$20.00
10/11/2024OppenheimerReiterated RatingOutperform ➝ Outperform$22.00 ➝ $22.00
10/1/2024WedbushInitiated CoverageOutperform$25.00
9/30/2024WedbushUpgradeStrong-Buy
9/25/2024Truist FinancialInitiated CoverageBuy$21.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/3/2024Cantor FitzgeraldReiterated RatingOverweight
8/16/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$29.00 ➝ $27.00
8/13/2024OppenheimerLower TargetOutperform ➝ Outperform$19.00 ➝ $17.00
7/25/2024Bank of AmericaInitiated CoverageBuy$24.00
6/25/2024Cantor FitzgeraldReiterated RatingOverweight
6/18/2024OppenheimerReiterated RatingOutperform ➝ Outperform
6/18/2024Cantor FitzgeraldReiterated RatingOverweight
6/14/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
5/14/2024Royal Bank Of CanadaInitiated CoverageOutperform$30.00
5/9/2024Cantor FitzgeraldInitiated CoverageOverweight
5/6/2024Lifesci CapitalReiterated RatingOutperform
4/9/2024B. RileyBoost TargetBuy ➝ Buy$12.00 ➝ $17.00
4/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$12.00 ➝ $15.00
3/19/2024OppenheimerReiterated RatingOutperform ➝ Outperform$12.00
1/26/2024B. RileyInitiated CoverageBuy$12.00
11/15/2023JonestradingInitiated CoverageBuy$14.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 18 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 12 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 12 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Perspective Therapeutics logo
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.39
Low: $2.17
High: $2.41

50 Day Range

MA: $2.94
Low: $2.05
High: $4.98

52 Week Range

Now: $2.39
Low: $1.60
High: $5.39

Volume

1,930,567 shs

Average Volume

1,946,208 shs

Market Capitalization

$177.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Perspective Therapeutics?

The following sell-side analysts have issued reports on Perspective Therapeutics in the last twelve months: B. Riley, Brookline Capital Management, BTIG Research, Cantor Fitzgerald, HC Wainwright, Lifesci Capital, Royal Bank Of Canada, Scotiabank, Truist Financial Corporation, UBS Group AG, and Wedbush.
View the latest analyst ratings for CATX.

What is the current price target for Perspective Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Perspective Therapeutics in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 381.2%. Royal Bank Of Canada has the highest price target set, predicting CATX will reach $16.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $7.00 for Perspective Therapeutics in the next year.
View the latest price targets for CATX.

What is the current consensus analyst rating for Perspective Therapeutics?

Perspective Therapeutics currently has 6 buy ratings and 4 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CATX will outperform the market and that investors should add to their positions of Perspective Therapeutics.
View the latest ratings for CATX.

What other companies compete with Perspective Therapeutics?

Other companies that are similar to Perspective Therapeutics include Bioventus, CeriBell, Tactile Systems Technology, Avanos Medical and NeuroPace. Learn More about companies similar to Perspective Therapeutics.

How do I contact Perspective Therapeutics' investor relations team?

Perspective Therapeutics' physical mailing address is 2401 Elliott Avenue, Suite 320, Seattle, WA 98121, United States. The company's listed phone number is 206-676-0900 and its investor relations email address is [email protected]. The official website for Perspective Therapeutics is www.perspectivetherapeutics.com. Learn More about contacing Perspective Therapeutics investor relations.